Considering treatment with selective COX-2 inhibitors, celecoxib resulted in a pre-operative randomized phase II trial in an anti-tumor transcriptional response in primary breast cancer with a substantial decrease in Ki-67 positive cells as compared to placebo [6]. This evidence concerns the gene PTGS2 and breast carcinoma.